Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECOVER real-world outcomes after triple combination modulator therapy in cystic fibrosis
ISRCTN53454974Phase 4Active, not recruiting
- Sponsor
- RCSI University of Medicine and Health Sciences
- Start
- Aug 2020
- Modality
- Small Molecules
01
Overview
Phase 4, open-label trial of elexacaftor and adapalene + clindamycin in cystic fibrosis (CF) (2 cohorts), sponsored by RCSI University of Medicine and Health Sciences. Started Aug 2020; status: active, not recruiting.
02
Drugs
elexacaftoradapalene + clindamycin
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on ISRCTN53454974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN53454974.